Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Uveitis is inflammation of the uvea, which is the middle layer of the eye that consists of the iris, ciliary body and choroid. Based on the location where the inflammation occurs in the uvea, the condition can be classified as: anterior uveitis, intermediate uveitis, posterior uveitis, and diffuse uveitis.
The global uveitis treatment market is estimated to account for US$ 648.4 Mn in terms of value in 2020 and is expected to reach US$ 1,036.0 Mn by the end of 2027.
Global Uveitis Treatment Market: Drivers
High prevalence of uveitis is expected to propel growth of the global uveitis treatment over the forecast period. For instance, according to the study, ‘Epidemiology of uveitis in urban Australia’, published in April 2019 in the journal Clinical and Experimental Ophthalmology, the incidence of uveitis was 21.54 per 100 000 person?years. The period prevalence of the condition was 36.27 per 100 000 persons.
Moreover, high incidence of autoimmune disorders is also expected to aid in growth of the market. For instance, according to a study by National MS Society, published in February 2019, in the journal Neurology, in 2017, nearly 1 million adults were living with multiple sclerosis in the U.S.
Corticosteroids held dominant position in the global uveitis treatment market in 2019, accounting for 21.1% share in terms of value, followed by Monoclonal Antibodies and Antibiotics, respectively.
Figure 1. Global Uveitis Treatment Market Share (%), by Value, by Treatment Type, 2019
Global Uveitis Treatment Market: Restraints
Limited studies on efficacy comparison of treating agents are expected to hinder growth of the market. Due to the presence of very few studies regarding the efficacy of the agents used for treating uveitis, there have been very limited first line drugs, which are introduced for the treatment. Under various forms of uveitis, varying behavior of the patients have been observed with varying diagnoses and success in the treatment.
Moreover, challenging manufacturing process is also expected to limit the market growth. Eye care product needs unique manufacturing process for making the product appropriately aligned with the GMP regulations for sterile products. Since the formulations are prone to get affected by the pathogens available in the environment, they are formulated under highly protected area.
Uveitis Treatment Market Report Coverage
||Market Size in 2019:
||US$ 605.7 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 1,036.0 Mn
- North America: U.S., Canada
- Latin America: Brazil, Argentina, Mexico, Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
- Middle East: GCC Countries, Israel, Rest of Middle East
- Africa: South Africa, North Africa, Central Africa
- By Treatment Type: Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal, Analgesics.
- By Disease Type: Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Pan uveitis.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores.
Allergan, Inc., Novartis AG, Valeant Pharmaceuticals International, Inc., Galapagos, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Inc., AbbVie Inc., Tarsius Pharma, Eyegate Pharmaceuticals, Inc., Alimera Sciences Inc., and pSivida Corp.
- High prevalence of uveitis
- Number of treatment options
|Restraints & Challenges:
- Limited studies on efficacy comparison of treating agents
- Challenging manufacturing process
Global Uveitis Treatment Market: Opportunities
Promising compounds in clinical trials are expected to offer lucrative growth opportunities for players in the global uveitis treatment over the forecast period. For instance, in June 2020, Tarsius Pharma, a clinical-stage biopharmaceutical company, completed patient enrollment in the company's Phase I/II trial of TRS01 in patients with active anterior non-infectious uveitis.
High incidence of rheumatoid arthritis is also expected to aid in growth of the market. For instance, according to the study, “Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017”, published in the journal Annals of the Rheumatic Diseases, in November 2019, the age-standardized point prevalence and annual incidence rates of rheumatoid arthritis were 246.6 and 14.9 in 2017, which increased by 7.4% and 8.2% from 1990, respectively.
The global uveitis treatment market was valued at US$ 605.7 Mn in 2019 and is forecast to reach a value of US$ 1,036.0 Mn by 2027 at a CAGR of 6.9% between 2020 and 2027.
Figure 2. Global Uveitis Treatment Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027
Market Trends/Key Takeaways
The prevalence of anterior uveitis is high in Asia Pacific. For instance, according to the study, ‘Epidemiology of uveitis in urban Australia’, published in April 2019 in the journal Clinical and Experimental Ophthalmology, the distribution of prevalent uveitis cases was anterior (75%), intermediate (6%), posterior (15%) and panuveitis (4%).
The emergence of Covid-19 has halted several clinical trials. For instance, in March 2020, Belgium-based Galapagos announced that the company is pausing enrollment in some clinical trials that include its Phase II and Phase III trials of filgotinib in Crohn’s disease, psoriatic arthritis and uveitis.
Global Uveitis Treatment Market: Competitive Landscape
Major players operating in the global uveitis treatment market include, Allergan, Inc., Novartis AG, Valeant Pharmaceuticals International, Inc., Galapagos, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Inc., AbbVie Inc., Tarsius Pharma, Eyegate Pharmaceuticals, Inc., Alimera Sciences Inc., and pSivida Corp.
Global Uveitis Treatment Market: Key Developments
Major players in the market are focused on R&D of new products to expand their product portfolio. For instance, in March 2020, EyePoint Pharmaceuticals, Inc. announced positive topline 36-month follow-up data from the second Phase 3 trial of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
Major players in the market are also focused on approval and launch of new products to expand their product portfolio. For instance, in December 2019, Alimera Sciences, Inc. was granted marketing authorization for ILUVIEN for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye, in Belgium, The Netherlands, and Luxembourg.